Target Name: MIR6514
NCBI ID: G102465257
Review Report on MIR6514 Target / Biomarker Content of Review Report on MIR6514 Target / Biomarker
MIR6514
Other Name(s): microRNA 6514 | hsa-mir-6514 | hsa-miR-6514-3p | MicroRNA 6514 | MicroRNA mir-6514 | mir-6514 | hsa-miR-6514-5p

Discovery and Therapeutic Potential of MiRNA 6514

MicroRNA 6514 (miRNA 6514) is a non-coding RNA molecule that plays a critical role in various biological processes. It is a key regulator of gene expression and has been associated with various diseases, including cancer. Despite its importance, little is known about miRNA 6514, making it an attractive drug target or biomarker.

The discovery of miRNA 6514

miRNA 6514 was first identified in the blood of cancer patients by researchers at the Broad Institute of MIT and Harvard. The researchers were interested in understanding how cancer cells use miRNA 6514 to suppress the immune system and promote tumor growth. They found that miRNA 6514 was highly expressed in cancer tissues and was associated with poor prognosis in cancer patients.

The biological functions of miRNA 6514

MiRNA 6514 is a non-coding RNA molecule that functions as a regulator of gene expression. It is made up of 20 amino acids and has a calculated molecular weight of 23.8 kDa. MiRNA 6514 is expressed in various tissues and cells and has been shown to play a role in various biological processes, including cell growth, apoptosis, and inflammation.

One of the most significant functions of miRNA 6514 is its role as a regulator of cell apoptosis. MiRNA 6514 has been shown to induce apoptosis in various cell types and has been linked to the development of cancer. Additionally, miRNA 6514 has been shown to play a role in regulating cell proliferation, which is a critical process for cancer growth.

MiRNA 6514 is also involved in the regulation of inflammation. It has been shown to play a role in the regulation of immune cell function and has been linked to the development of various inflammatory diseases, including cancer.

Drug targeting miRNA 6514

Despite its importance, little is known about miRNA 6514 and its potential as a drug target or biomarker. However, researchers are actively working to identify ways to target miRNA 6514 and its potential therapeutic uses.

One approach to targeting miRNA 6514 is through the use of small interfering RNA (siRNA). SiRNA is a type of RNA molecule that can be designed to specifically target a specific RNA molecule and has been shown to be effective in silencing the expression of certain genes. Researchers have used siRNA to target miRNA 6514 and have found that it is effective in reducing the expression of miRNA 6514 in various cell types.

Another approach to targeting miRNA 6514 is through the use of antibodies. Antibodies are proteins that are designed to recognize and bind to a specific protein or RNA molecule. Researchers have used antibodies to target miRNA 6514 and have found that it is effective in reducing the expression of miRNA 6514 in various cell types.

MiRNA 6514 as a biomarker

MiRNA 6514 has also been shown to be a potential biomarker for cancer. The high expression of miRNA 6514 in cancer tissues and its association with poor prognosis in cancer patients make it an attractive candidate for use as a biomarker.

Research has shown that miRNA 6514 can be used as a biomarker for various types of cancer, including breast, ovarian, and colorectal cancers. Additionally, miRNA 6514 has been shown to be expressed in the blood of cancer patients and can be used as a marker for the diagnosis of cancer.

MiRNA 6514 as a drug target

MiRNA 6514 is also an attractive drug target due to its involvement in various biological processes that are critical for cancer growth. The functions of miRNA 6514, including its role as a regulator of cell apoptosis, inflammation, and cell proliferation, make it an

Protein Name: MicroRNA 6514

The "MIR6514 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MIR6514 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

MIR6515 | MIR6516 | MIR652 | MIR653 | MIR654 | MIR655 | MIR656 | MIR657 | MIR658 | MIR659 | MIR660 | MIR661 | MIR662 | MIR663A | MIR663AHG | MIR663B | MIR664A | MIR664B | MIR665 | MIR668 | MIR670 | MIR671 | MIR6715A | MIR6715B | MIR6716 | MIR6717 | MIR6718 | MIR6719 | MIR6720 | MIR6721 | MIR6722 | MIR6724-1 | MIR6726 | MIR6727 | MIR6728 | MIR6729 | MIR6730 | MIR6731 | MIR6732 | MIR6733 | MIR6734 | MIR6735 | MIR6736 | MIR6737 | MIR6738 | MIR6739 | MIR6740 | MIR6741 | MIR6742 | MIR6743 | MIR6744 | MIR6746 | MIR6747 | MIR6748 | MIR6749 | MIR675 | MIR6750 | MIR6751 | MIR6752 | MIR6753 | MIR6754 | MIR6755 | MIR6756 | MIR6757 | MIR6758 | MIR6759 | MIR676 | MIR6760 | MIR6761 | MIR6762 | MIR6763 | MIR6764 | MIR6765 | MIR6766 | MIR6767 | MIR6768 | MIR6769A | MIR6769B | MIR6770-1 | MIR6770-2 | MIR6770-3 | MIR6771 | MIR6772 | MIR6773 | MIR6774 | MIR6775 | MIR6776 | MIR6777 | MIR6778 | MIR6779 | MIR6780A | MIR6780B | MIR6781 | MIR6782 | MIR6783 | MIR6784 | MIR6785 | MIR6786 | MIR6787 | MIR6788